CTEC ConvaTec Group Plc

Convatec Group PLC:

Convatec Group PLC (CTEC)
Convatec Group PLC:

31-Oct-2022 / 12:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


31 October 2022

Convatec Group Plc
("Convatec" or "the Company")

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 October 2022, the Company's issued capital with voting rights consisted of 2,043,872,048 ordinary shares of 10p each (‘Shares’). The Company does not hold any Shares in Treasury at the date of this disclosure.

The above figure (2,043,872,048) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 

 

Enquiries 

Analysts and Investors 

Kate Postans, VP Investor Relations, Convatec                                                            +44 (0)782 644 7807 

 

 

Media 

Buchanan: Charles Ryland / Chris Lane                                                                         +44 (0)207 466 5000                                            

Convatec Group Plc’s LEI code is 213800LS272L4FIDOH92 

 

About Convatec 
 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. With around 10,000 colleagues, and a promise to be forever caring, our products and services are available in over 100 countries. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. The company is a constituent of the FTSE 100 Index (LSE:CTEC) and in 2021 revenues were over $2 billion. To learn more about Convatec, please visit



ISIN: GB00BD3VFW73
Category Code: TVR
TIDM: CTEC
LEI Code: 213800LS272L4FIDOH92
Sequence No.: 196178
EQS News ID: 1469733

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1469733&application_name=news&site_id=research_pool
EN
31/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ConvaTec Group Plc

Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...

Martin Hall
  • Martin Hall

Hardman & Co Insight: Survival of the UK life sciences sector

For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway...

 PRESS RELEASE

Convatec Group PLC: Director/ PDMR Shareholding

Convatec Group PLC (CTEC) Convatec Group PLC: Director/ PDMR Shareholding 12-March-2024 / 16:00 GMT/BST 12 March 2024 Convatec Group Plc(“Convatec” or “the Company”) Director/ PDMR Shareholding  The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility (“PDMR”) in respect of ordinary shares of 10 pence each in the Company (“Shares”). Grant of Awards under the Company’s Long Term Incentive Plan (“LTIP”)   On the 11 March 2024, awards were granted to Karim Bitar, Chief Executive Officer and Jonny Mason, Chief Fin...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch